Median-based incremental cost-effectiveness ratios with censored data

References

• Bang, H., Tsiatis, A. A. (2000). Estimating medical costs with censored data. Biometrika 87:329–343.
   Web of Science ®Google Scholar
• Bang, H., Tsiatis, A. A. (2002). Median regression with censored cost data. Biometrics 58:643–649.
   PubMed Web of Science ®Google Scholar
• Bang, H., Zhao, H. (2012a). Average cost-effectiveness ratio with censored data. Journal of Biopharmaceutical Statistics 22:401–415.
   PubMed Web of Science ®Google Scholar
• Bang, H., Zhao, H. (2012b). Median-based incremental cost-effectiveness ratio (ICER). Journal of Statistical Theory and Practice 6:428–442.
   PubMedGoogle Scholar
• Bang, H., Zhao, H. (2014). Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis. Journal of Biopharmaceutical Statistics 24:443–460.
   PubMed Web of Science ®Google Scholar
• Barber, J. A., Thompson, S. G. (2000). Analysis of cost data in randomized trials: An application of the non-parametric bootstrap. Statistics in Medicine 19:3219–3236.
   PubMed Web of Science ®Google Scholar
• Barker, C. (2009). The mean, median, and confidence intervals of the Kaplan–Meier survival estimate—computations and applications. The American Statistician 63:78–80.
   Web of Science ®Google Scholar
• Black, W. C. (1990) The CE plane: a graphic representation of cost-effectiveness. Medical Decision Making 10:212–214.
   PubMed Web of Science ®Google Scholar
• Boos, D. D., Stefanski, L. A. (2013). Essential Statistical Inference. New York: Springer.
   Google Scholar
• Brookmeyer, R. (2005). Median survival time. Encyclopedia of Biostatistics. 5.
   Google Scholar
• CONSORT. (2010). http://www.consort-statement.org/checklists/view/657-harms/1014-outcomes-and-estimation.
   Google Scholar
• Cordony A., et al. (2008). Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice. Value in Health 11:4–12.
   PubMed Web of Science ®Google Scholar
• Efron, B., Tibshirani, R. J. (1993). An Introduction to the Bootstrap. Boca Raton: Chapman and Hall.
   Google Scholar
• Fenwick, E., Claxton, K., Sculpher, M. J. (2001). Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics 10:779–787.
   PubMed Web of Science ®Google Scholar
• Fowler, R., et al. (2014). Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients, JAMA 312:2135–2145.
   PubMed Web of Science ®Google Scholar
• Gardiner, J., Susarla, V., Van Ryzin, J. (1986). Estimation of the median survival time under random censorship. In: Adaptive Statistical Procedures and Related Topics(pp. 350–364). Hayward, CA: Institute of Mathematical Statistics.
   Google Scholar
• Gardiner, J. C., Bradley, C. J., Huebner, M. (2000). The cost-effectiveness ratio in the analysis of health care programs. Handbook of Statistics, Bioenvironmental and Public Health Statistics in Medicine 18:841–869.
   Google Scholar
• Gold, M. R., et al. (1996). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press.
   Google Scholar
• Guyot, P., et al. (2011). Survival time outcomes in randomized, controlled trials and meta-analyses: The parallel universes of efficacy and cost-effectiveness. Value in Health 14:640–646.
   PubMed Web of Science ®Google Scholar
• Hoch, J. S., Smith, M. W. (2006). A guide to economic evaluation: methods for cost-effectiveness analysis of person-level data. Journal of Traumatic Stress 19:787–797.
   PubMed Web of Science ®Google Scholar
• Huang, Y. (2009). Cost analysis with censored data. Medical Care 47:S115–119.
   Web of Science ®Google Scholar
• Laska, E. M., Meisner, M., Siegel, C. (1997). The usefulness of average cost-effectiveness ratios. Health Economics 6:497–504.
   PubMed Web of Science ®Google Scholar
• Laupacis, A., et al. (1992). How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146:474–481.
   Google Scholar
• Lin, D. Y., et al. (1997). Estimating medical costs from incomplete follow-up data. Biometrics 53:419–434.
   PubMed Web of Science ®Google Scholar
• Moss, A., et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. NEJM 346:877–883.
   PubMed Web of Science ®Google Scholar
• Moss, A.J., et al. (1996). Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. NEJM 335:1933–1940.
   PubMed Web of Science ®Google Scholar
• Mushlin, A.I., et al. (1998). The cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT. Circulation 97:2129–2135.
   PubMed Web of Science ®Google Scholar
• Obenchain, R. L. (1999). Resampling and multiplicity in cost-effectiveness inference. Journal of Biopharmaceutical Statistics 9:563–582.
   PubMedGoogle Scholar
• Price, R. M., Bonnet, D. G. (2002). Distribution-free confidence intervals for difference and ratio of medians. Journal of Statistical Computation and Simulation 72:119–124.
   Web of Science ®Google Scholar
• Ramsey, S., et al. (2005). Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value in Health 8:521–533.
   PubMed Web of Science ®Google Scholar
• Sima, C. S., Gonen, M. (2013). Optimal cutpoint estimation with censored data. Journal of Statistical Theory and Practice 7:345–359.
   Google Scholar
• Thompson, S. G., Barber, J. A. (2000). How should cost data in pragmatic randomised trials be analysed? BMJ 329:1197–1200.
   Web of Science ®Google Scholar
• Ubel, P. A., et al. (2003). What is the price of life and why doesn’t it increase at the rate of inflation? Archives of Internal Medicine 163:1637–1641.
   Web of Science ®Google Scholar
• Vu, T., et al. (2008). Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: A population-based evaluation. Annals of Oncology 19:461–464.
   PubMed Web of Science ®Google Scholar
• Wahed, A. (2011). On the equivalence of inverse-probability-of-censoring-weighted and Kaplan–Meier estimators. Journal of the Applied Statistical Science 18. URL https://www.novapublishers.com/catalog/product_info.php?products_id=29712
   Google Scholar
• Wang, H., Zhao, H. (2006). Estimating incremental cost-effectiveness ratios and their confidence intervals with differentially censored data. Biometrics 62:570–575.
   PubMed Web of Science ®Google Scholar
• Wang, H., Zhao, H. (2008). A study on confidence intervals for incremental cost-effectiveness ratios. Biometrical Journal 50:505–514.
   PubMed Web of Science ®Google Scholar
• Weinstein, M. C., et al. (1996). Recommendations for reporting cost-effectiveness analyses, for the Panel on Cost-Effectiveness in Health and Medicine. JAMA 276:1253–1258.
   PubMed Web of Science ®Google Scholar
• Willan, A., Lin, D. (2001). Incremental net benefit in randomized clinical trials. Statistics in Medicine 20:1563–1574.
   PubMed Web of Science ®Google Scholar
• Willan, A., et al. (2002). Using inverse-weighting in cost-effectiveness analysis with censored data. Statistical Methods in Medical Research 11:539–551.
   PubMed Web of Science ®Google Scholar
• Ying, Z., Jung, S.-H., Wei, L.J. (1995). Survival analysis with median regression models. JASA 90:178–184.
   Web of Science ®Google Scholar
• Zhao, H., Tian, L. (2001). On estimating medical cost and incremental cost-effectiveness ratios with censored data. Biometrics 57:1002–1008.
   PubMed Web of Science ®Google Scholar
• Zhao, H., et al. (2012). Nonparametric inference for median costs with censored data. Biometrics 68:717–725.
   PubMed Web of Science ®Google Scholar
• Zwanziger, J., et al. (2006). The cost effectiveness of implantable cardioverter-defibrillators: Results from the MADIT-II. JACC 47:2310–2318.
   Web of Science ®Google Scholar